Zydus Life shares in focus after Ahmedabad injectables unit clears USFDA inspection
Published on 20/02/2026 07:08 AM
Zydus Life shares in focus after Ahmedabad injectables unit clears USFDA inspectionA clean inspection outcome is typically seen as a positive regulatory signal for pharmaceutical manufacturers, particularly in the injectables segment, where compliance standards are stringent and approvals are closely linked to future product launches in the United States market.By CNBC-TV18 February 20, 2026, 7:08:10 AM IST (Updated)1 Min Read(Photo Credit : CNBC-TV18 Library )Zydus Lifesciences shares will be in focus today (February 20) after the company said the United States Food and Drug Administration (USFDA) has completed a pre-approval inspection (PAI) at its Injectable Medical Devices facility in Ahmedabad with zero observations.
The inspection was conducted at the company’s Unit-9 plant at Zydus Biotech Park, Changodar, between February 16 and 19, 2026, the company said in an exchange filing dated February 19.
A clean inspection outcome is typically seen as a positive regulatory signal for pharmaceutical manufacturers, particularly in the injectables segment, where compliance standards are stringent and approvals are closely linked to future product launches in the United States market.
Over the last couple of the days, the Ahmedabad-based pharma company also received final approval from the USFDA for bosentan tablets used for the treatment of pulmonary arterial hypertension (PAH). and announced the launch of ANYRA for advanced eye care.
Shares of Zydus closed nearly 1% lower on February 19 at ₹901.35 apiece. The shares have shed around 1.5% so far this year. Continue ReadingFirst Published: Feb 20, 2026 7:07 AM ISTTagsUSFDAZydus Lifesciences